WO2018125930A1 - Dispositif d'administration de médicament intraoculaire et procédés associés - Google Patents

Dispositif d'administration de médicament intraoculaire et procédés associés Download PDF

Info

Publication number
WO2018125930A1
WO2018125930A1 PCT/US2017/068571 US2017068571W WO2018125930A1 WO 2018125930 A1 WO2018125930 A1 WO 2018125930A1 US 2017068571 W US2017068571 W US 2017068571W WO 2018125930 A1 WO2018125930 A1 WO 2018125930A1
Authority
WO
WIPO (PCT)
Prior art keywords
active agent
eye
biodegradable
acid
matrix
Prior art date
Application number
PCT/US2017/068571
Other languages
English (en)
Inventor
Balamurali K. Ambati
Bruce K. Gale
Srinivas Rao CHENNAMANENI
Original Assignee
University Of Utah Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/391,666 external-priority patent/US10588855B2/en
Application filed by University Of Utah Research Foundation filed Critical University Of Utah Research Foundation
Priority to CA3050771A priority Critical patent/CA3050771A1/fr
Priority to JP2019555741A priority patent/JP2020514404A/ja
Priority to KR1020197022221A priority patent/KR20190110101A/ko
Priority to CN201780087539.7A priority patent/CN110337296A/zh
Priority to EP17885743.9A priority patent/EP3562489A4/fr
Priority to AU2017388230A priority patent/AU2017388230A1/en
Publication of WO2018125930A1 publication Critical patent/WO2018125930A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La présente invention concerne des dispositifs, des systèmes et des procédés d'administration d'un agent actif de la capsule du cristallin vers un segment postérieur de l'œil d'un sujet qui peuvent comprendre un dispositif d'administration d'agent actif intraoculaire comprenant un agent actif dispersé dans une matrice d'agent actif biodégradable. L'agent actif comprend de la dexaméthasone et le dispositif d'administration est adapté pour s'ajuster dans une capsule de cristallin ou un sulcus ciliaire d'un œil. Le dispositif d'administration peut être inséré dans la capsule de cristallin ou le sulcus ciliaire d'un œil pendant une chirurgie de la cataracte ou pour le traitement de l'uvéite.
PCT/US2017/068571 2016-12-27 2017-12-27 Dispositif d'administration de médicament intraoculaire et procédés associés WO2018125930A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA3050771A CA3050771A1 (fr) 2016-12-27 2017-12-27 Dispositif d'administration de medicament intraoculaire et procedes associes
JP2019555741A JP2020514404A (ja) 2016-12-27 2017-12-27 眼内薬物送達デバイス及び関連方法
KR1020197022221A KR20190110101A (ko) 2016-12-27 2017-12-27 안구내 약물 전달 장치 및 관련 방법들
CN201780087539.7A CN110337296A (zh) 2016-12-27 2017-12-27 眼内药物递送装置和相关方法
EP17885743.9A EP3562489A4 (fr) 2016-12-27 2017-12-27 Dispositif d'administration de médicament intraoculaire et procédés associés
AU2017388230A AU2017388230A1 (en) 2016-12-27 2017-12-27 Intraocular drug delivery device and associated methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/391,666 US10588855B2 (en) 2008-05-12 2016-12-27 Intraocular drug delivery device and associated methods
US15/391,666 2016-12-27

Publications (1)

Publication Number Publication Date
WO2018125930A1 true WO2018125930A1 (fr) 2018-07-05

Family

ID=62709865

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/068571 WO2018125930A1 (fr) 2016-12-27 2017-12-27 Dispositif d'administration de médicament intraoculaire et procédés associés

Country Status (7)

Country Link
EP (1) EP3562489A4 (fr)
JP (1) JP2020514404A (fr)
KR (1) KR20190110101A (fr)
CN (1) CN110337296A (fr)
AU (1) AU2017388230A1 (fr)
CA (1) CA3050771A1 (fr)
WO (1) WO2018125930A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11298262B2 (en) 2018-07-23 2022-04-12 The Regents Of The University Of Colorado, A Body Corporate Ophthalmic device for drug delivery
US11399977B2 (en) 2020-06-04 2022-08-02 SpyGlass Pharma, Inc. Ophthalmic implant system for drug delivery
JP2022535223A (ja) * 2019-05-31 2022-08-05 サムジン ファーマシューティカル カンパニー，リミテッド 眼疾患治療用組成物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022538347A (ja) 2019-06-27 2022-09-01 レイヤーバイオ，インコーポレーテッド 眼用デバイス送達方法およびシステム

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017900A1 (fr) * 1993-12-30 1995-07-06 Arcturus Pharmaceutical Corporation Methodes de traitement de troubles du systeme nerveux central ou de l'oeil impliquant des voies d'oxydation pathogene
US20110230963A1 (en) * 2008-11-20 2011-09-22 Insight Innovations, Llc Biocompatible biodegradable intraocular implant system
US20130302398A1 (en) * 2008-05-12 2013-11-14 Balamurali K. Ambati Intraocular drug delivery device and associated methods
US8663194B2 (en) * 2008-05-12 2014-03-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US7931909B2 (en) * 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
EP1998718A1 (fr) * 2006-03-30 2008-12-10 Universite De Geneve Cristallin artificiel intégrant un système de libération de médicament
CN101827523A (zh) * 2007-08-16 2010-09-08 马库赛特公司 用于治疗眼部疾病或病症的制剂
JP5222550B2 (ja) * 2007-12-27 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
JP6543431B2 (ja) * 2013-10-10 2019-07-10 ユニバーシティー オブ ユタ リサーチ ファウンデーションＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｕｔａｈ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 眼内薬物送達デバイスおよび付随する方法
CA2830555A1 (fr) * 2013-10-18 2015-04-18 University Of Utah Research Foundation Dispositif d'administration intraoculaire de medicament et procedes associes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017900A1 (fr) * 1993-12-30 1995-07-06 Arcturus Pharmaceutical Corporation Methodes de traitement de troubles du systeme nerveux central ou de l'oeil impliquant des voies d'oxydation pathogene
US20130302398A1 (en) * 2008-05-12 2013-11-14 Balamurali K. Ambati Intraocular drug delivery device and associated methods
US8663194B2 (en) * 2008-05-12 2014-03-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US20110230963A1 (en) * 2008-11-20 2011-09-22 Insight Innovations, Llc Biocompatible biodegradable intraocular implant system

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Cystoid Macular Edema", EYEWIKI, 26 January 2014 (2014-01-26), XP055510427, Retrieved from the Internet <URL:https://web.archive.org/web/20140126073222/ http://eyewiki.aao.org/Cystoid_Macular_Edema> [retrieved on 20180225] *
NORMAL POLYMERS, 31 January 2016 (2016-01-31), Retrieved from the Internet <URL:https://web.archive.org/web/20160131164109/http://normalpolymer.com/poly-DL-lactide-co-glycolide.php> [retrieved on 20180223] *
See also references of EP3562489A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11298262B2 (en) 2018-07-23 2022-04-12 The Regents Of The University Of Colorado, A Body Corporate Ophthalmic device for drug delivery
JP2022535223A (ja) * 2019-05-31 2022-08-05 サムジン ファーマシューティカル カンパニー，リミテッド 眼疾患治療用組成物
US11399977B2 (en) 2020-06-04 2022-08-02 SpyGlass Pharma, Inc. Ophthalmic implant system for drug delivery
US11617681B2 (en) 2020-06-04 2023-04-04 SpyGlass Pharma, Inc. Ophthalmic implant system for drug delivery
US11903874B2 (en) 2020-06-04 2024-02-20 SpyGlass Pharma, Inc. Ophthalmic implant system for drug delivery

Also Published As

Publication number Publication date
AU2017388230A1 (en) 2019-08-15
CN110337296A (zh) 2019-10-15
CA3050771A1 (fr) 2018-07-05
EP3562489A1 (fr) 2019-11-06
JP2020514404A (ja) 2020-05-21
KR20190110101A (ko) 2019-09-27
EP3562489A4 (fr) 2020-07-29

Similar Documents

Publication Publication Date Title
US9877973B2 (en) Intraocular drug delivery device and associated methods
US20230172842A1 (en) Sustained drug delivery implant
US10064819B2 (en) Intraocular drug delivery device and associated methods
TWI332846B (en) Ocular implant made by a double extrusion process
Chennamaneni et al. Development of a novel bioerodible dexamethasone implant for uveitis and postoperative cataract inflammation
JP2022001582A (ja) 眼において薬物徐放を達成する方法及び生体適合性組成物
CA2830555A1 (fr) Dispositif d&#39;administration intraoculaire de medicament et procedes associes
WO2018125930A1 (fr) Dispositif d&#39;administration de médicament intraoculaire et procédés associés
Eperon et al. A biodegradable drug delivery system for the treatment of postoperative inflammation
KR20230067641A (ko) 생체 침식성 안구 약물 전달 삽입물 및 치료 방법
US10588855B2 (en) Intraocular drug delivery device and associated methods
WO2014066644A1 (fr) Systèmes d&#39;administration de médicament à libération prolongée contenant du kétorolac
JP6543431B2 (ja) 眼内薬物送達デバイスおよび付随する方法
AU2019204106A1 (en) Intraocular drug delivery device and associated methods
TW202110445A (zh) 治療眼部疾病之組合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17885743

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019555741

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 3050771

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 20197022221

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017885743

Country of ref document: EP

Effective date: 20190729

ENP Entry into the national phase

Ref document number: 2017388230

Country of ref document: AU

Date of ref document: 20171227

Kind code of ref document: A